Philadelphia Trust Company’s Humacyte HUMA Stock Holding History

Philadelphia Trust Company’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,000	Closed	-$17K	–	249
2025 Q1	$17K	Hold	10,000	–	–	﹤0.01%	242
2024 Q4	$51K	Hold	10,000	–	–	﹤0.01%	242
2024 Q3	$54K	Hold	10,000	–	–	﹤0.01%	246
2024 Q2	$48K	Hold	10,000	–	–	﹤0.01%	225
2024 Q1	$31K	Hold	10,000	–	–	﹤0.01%	236
2023 Q4	$28K	Hold	10,000	–	–	﹤0.01%	220
2023 Q3	$29K	Hold	10,000	–	–	﹤0.01%	218
2023 Q2	$29K	Hold	10,000	–	–	﹤0.01%	228
2023 Q1	$31K	Hold	10,000	–	–	﹤0.01%	229
2022 Q4	$21K	Hold	10,000	–	–	﹤0.01%	222
2022 Q3	$33K	Hold	10,000	–	–	﹤0.01%	210
2022 Q2	$32K	Hold	10,000	–	–	﹤0.01%	216
2022 Q1	$71K	Hold	10,000	–	–	0.01%	237
2021 Q4	$73K	Sell	10,000 -5,000	-33%	-$49.5K	0.01%	221
2021 Q3	$174K	Hold	15,000	–	–	0.01%	215
2021 Q2	$153K	Hold	15,000	–	–	0.01%	220
2021 Q1	$162K	Buy	+15,000	New	+$164K	0.01%	209

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Philadelphia Trust Company's HUMA Position: Q2 2025 in Review

Philadelphia Trust Company sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 10,000 shares — an estimated $17K sold.

Philadelphia Trust Company first reported a position in HUMA in Q1 2021 and held it in 17 quarters. The position peaked at $174K in Q3 2021. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

Philadelphia Trust Company reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
Philadelphia Trust Company sold 10,000 Humacyte shares in Q2 2025, an estimated $17K.
Philadelphia Trust Company first reported a position in Humacyte in Q1 2021 and held it in 17 quarters.
Philadelphia Trust Company's Humacyte position peaked at $174K in Q3 2021.
156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on Philadelphia Trust Company's 13F filing for Q2 2025, filed 13 Aug 2025.